Dostinex 0 5 mg
Dostinex 0 5 mg is a brand name form of a drug called cabergoline that is sometimes used for fertility treatment. This drug is called a dopamine agonist that simulates dopamine in the brain. Cabergoline can be used to deal with high levels of a chemical element called prolactin that comes from the pituitary gland. Medical research has shown that these cerebral type chemicals can have some specific results in the reproductive process for women, and fertility doctors now contemplate the use of this specific pharmaceutical agent for pregnancy-related treatments.
Dostinex 0 5 mg Description.
Dostinex 0 5 mg Tablets contain cabergoline, a dopamine receptor agonist. The chemical name for cabergoline is 1-[(6-allylergolin-8β-yl)-carbonyl]-1-[3-(dimethylamino) propyl]-3-ethylurea. Its empirical formula is C26H37N5O2, and its molecular weight is 451.62. The structural formula is as follows:
Cabergoline is a white powder soluble in ethyl alcohol, chloroform, and N, N-dimethylformamide (DMF); slightly soluble in 0.1N hydrochloric acid; very slightly soluble in n-hexane; and insoluble in water.
Dostinex 0.5 mg Tablets, for oral administration, contain 0.5 mg of cabergoline. Inactive ingredients consist of leucine, USP, and lactose, NF.
Dostinex 0 5 mg Warnings.
Post marketing cases of cardiac valvulopathy have been reported in patients receiving Dostinex. These cases have generally occurred during long-term administration of high doses of Dostinex (>2mg/day) used for the treatment of Parkinson’s disease. Rare cases have been reported associated with short-term treatment (<6 months) or in patients receiving lower doses for the treatment of hyperprolactinemia.
Physicians should use the lowest effective dose of Dostinex for the treatment of hyperprolactinemia and should periodically reassess the need for continuing therapy with Dostinex. In addition, patients receiving long term treatment with Dostinex should undergo periodic reassessment of their cardiac status, and echocardiography should be considered. Any patient who develops signs or symptoms of cardiac disease, including dyspnea, edema, congestive heart failure, or a new cardiac murmur, while being treated with Dostinex should be evaluated for possible valvulopathy.
ostinex should be used with caution in patients who have hemodynamically significant valvular disease or have been exposed to other medications associated with valvulopathy.
Dopamine agonists in general should not be used in patients with pregnancy-induced hypertension, for example, preeclampsia eclampsia, and post partum hypertension, unless the potential benefit is judged to outweigh the possible risk.
Dosage and Administration.
The recommended dosage of Dostinex Tablets for initiation of therapy is 0.25 mg twice a week. Dosage may be increased by 0.25 mg twice weekly up to a dosage of 1 mg twice a week according to the patient’s serum prolactin level. Before initiating treatment, cardiovascular evaluation should be performed and echocardiography should be considered to assess for valvular disease.
Dosage increases should not occur more rapidly than every 4 weeks, so that the physician can assess the patient’s response to each dosage level. If the patient does not respond adequately, and no additional benefit is observed with higher doses, the lowest dose that achieved maximal response should be used and other therapeutic approaches considered. Patients receiving long term treatment with Dostinex should undergo periodic assessment of their cardiac status and echocardiography should be considered.
After a normal serum prolactin level has been maintained for 6 months. It may be discontinued, with periodic monitoring of the serum prolactin level to determine whether or when treatment with Dostinex should be reinstituted. The durability of efficacy beyond 24 months of therapy with Dostinex has not been established.
Side effects requiring immediate medical attention.
Along with its needed effects, cabergoline (the active ingredient contained in Dostinex) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking cabergoline:
- Bloating or swelling of the face, arms, hands, lower legs, or feet
- burning, crawling, itching, numbness, prickling, “pins and needles”, or tingling feelings
- cold sweats
- dizziness, faintness, or lightheadedness when getting up from lying or sitting position
- fast, irregular, pounding, or racing heartbeat or pulse
- general feeling of discomfort or illness
- rapid weight gain
- swelling around the eyes
- tingling of the hands or feet
- unusual tiredness or weakness
- unusual weight gain or loss
Incidence not known
- Chest pain or tightness
- continuing loss of appetite
- continuing or severe abdominal or stomach pain
- continuing or severe nausea and vomiting
- decreased ability to exercise
- increased frequency of urination
- loss of appetite
- lower abdominal or stomach pain
- lower back pain
- trouble breathing
Get emergency help immediately if any of the following symptoms of overdose occur while taking cabergoline:
Symptoms of overdose
- seeing, hearing, or feeling things that are not there
- stuffy nose
Side effects not requiring immediate medical attention.
Some side effects of cabergoline may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.
Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
- Difficulty having a bowel movement (stool)
- excess air or gas in the stomach or intestines
- full feeling
- lack or loss of strength
- passing gas
- Abdominal or stomach pain
- acid or sour stomach
- blemishes on the skin
- breast pain
- burning, itching, or stinging of the skin
- changes in vision
- difficulty with moving
- dry mouth or toothache
- feeling of constant movement of self or surroundings
- feeling of warmth
- heavy bleeding
- itching skin
- joint pain
- muscle aches and pains
- muscle stiffness
- redness of the face, neck, arms, and occasionally, upper chest
- runny nose
- sensation of spinning
- sleepiness or unusual drowsiness
- sore throat
- stomach discomfort or upset
- sudden sweating
- trouble sleeping
- weight loss
- Bloody nose
- difficulty in concentrating
- increased in sexual ability, desire, drive, or performance
- increased interest in sexual intercourse
Incidence not known
- Attack, assault, or force
- feeling that others are watching you or controlling your behavior
- feeling that others can hear your thoughts
- hair loss or thinning of the hair
- pathological gambling
- severe mood or mental changes
- unusual behavior